A Comparison of the Efficacy of Immunomodulatory-containing Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis-Reference-Cited by-同舟云学术

A Comparison of the Efficacy of Immunomodulatory-containing Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis

Published:2018-03 Issue:3 Volume:18 Page:163-173.e6
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Dimopoulos Meletios Athanasios,Kaufman Jonathan L.,White Darrell,Cook Gordon,Rizzo Maria,Xu Yingxin,Fahrbach Kyle,Gaudig Maren,Slavcev Mary,Dearden Lindsay,Lam Annette

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference15 articles.

1. Treatment options for relapsed and refractory multiple myeloma;Nooka;Blood,2015

2. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international Myeloma Working Group study;Kumar;Leukemia,2012

3. Therapy for relapsed multiple myeloma: guidelines from the Mayo stratification for myeloma and risk-adapted therapy;Dingli;Mayo Clin Proc,2017

4. Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients;Botta;Blood Adv,2017

5. Systematic literature review and network meta-analysis of treatment outcomes in relapsed and/or refractory multiple myeloma;van Beurden-Tan;J Clin Oncol,2017

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect modification in network meta-analyses for relapsed/refractory multiple myeloma: systematic review and meta-analysis;BMJ Open;2023-08

2. Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myeloma;Anti-Cancer Drugs;2023-04-06

3. Generic Lenalidomide Rivelime Versus Brand-name Revlimid® in the Treatment of Relapsed/Refractory Multiple Myeloma: A Retrospective Single-center Experience on Efficacy, Safety and Survival Outcome;Clinical Lymphoma Myeloma and Leukemia;2023-03

4. Network meta-analysis of efficacy of ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma;Hematology;2023-01-06

5. Lenalidomide-based triplet regimens in first relapsed multiple myeloma patients: real-world evidence from a propensity score matched analysis;Haematologica;2022-10-06